Financial Performance - The company's operating revenue for the reporting period was CNY 291,989,977.77, a decrease of 12.55% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 27,006,925.19, down 38.46% year-on-year[4] - The basic earnings per share decreased by 38.47% to CNY 0.3965[4] - The weighted average return on equity (ROE) decreased to 5.19% from 8.49% in the previous year[4] Assets and Growth - Total assets at the end of the reporting period were CNY 691,619,876.30, an increase of 4.88% from the beginning of the period[4] Market Challenges - The company faced a decline in revenue primarily due to delays in the market entry of new medical devices and increased competition in rehabilitation technology products[7] - The net profit decline was also attributed to increased sales expenses from expanding domestic and international sales channels[7] - The company achieved sales growth in certain new products, such as the variable amplitude fascia gun, but overall sales did not meet expectations[7] Regulatory Milestones - The company received 510K certification for its compression boot product, allowing legal sales in the U.S. market[7] Cautionary Notes - The company warns that the financial data presented is preliminary and has not been audited, urging investors to be cautious[9]
倍益康(870199) - 2024 Q4 - 年度业绩